Moreover, from our analysis and the work from Stavropoulou and colleagues [17] elevated expression of Zeb1 and potentially Zeb2 transcripts in the leukemic stem cell compartment may ultimately drive poor outcomes as opposed to overall expression of Zeb1/2 in bulk AML samples. The gene discussed is ZEB1; the disease is acute myeloid leukemia.